Log in

Relevant bibliographies by topics / Betrixaban

Contents

Journal articles

Academic literature on the topic 'Betrixaban'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Betrixaban.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Betrixaban"

1

Lee, Katie, Samantha Cham, and Sum Lam. "Betrixaban." Cardiology in Review 26, no. 6 (2018): 331–38. http://dx.doi.org/10.1097/crd.0000000000000227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gras, J. A. "Betrixaban." Drugs of the Future 37, no. 11 (2012): 761. http://dx.doi.org/10.1358/dof.2012.037.011.1902385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gras, J. A. "Betrixaban." Drugs of the Future 37, no. 11 (2012): 761. http://dx.doi.org/10.1358/dof.2012.37.11.1902385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Garland, Scott G., Christina E. DeRemer, Steven M. Smith, and John G. Gums. "Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients." Annals of Pharmacotherapy 52, no. 6 (2018): 554–61. http://dx.doi.org/10.1177/1060028018754383.

Full text

Abstract:

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the factor Xa (FXa) inhibitor betrixaban for extended-duration prophylaxis of acute medically ill patients with venous thromboembolism (VTE) risk factors. Data Sources: A MEDLINE/PubMed (January 1990 to October 2017) search was conducted using the following keywords: betrixaban, PRT054021, FXa inhibitor, novel oral anticoagulant, NOAC, direct oral anticoagulant, DOAC, and target specific oral anticoagulant, TSOAC. References of identified articles were searched by hand for additional relevant citations. Study Sele

APA, Harvard, Vancouver, ISO, and other styles

5

Hutchaleelaha, Athiwat, Christine Ye, Yonghong Song, Todd Lorenz, Daniel Gretler, and Joseph L. Lambing. "Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes." Blood 120, no. 21 (2012): 2266. http://dx.doi.org/10.1182/blood.v120.21.2266.2266.

Full text

Abstract:

Abstract Abstract 2266 Betrixaban is a once daily oral Factor Xa inhibitor being investigated in a Phase 3 clinical trial to prevent venous thromboembolism in acute medically ill patients (APEX Study). Mass balance, metabolite profile and interaction with major CYP enzymes were evaluated in this study. Portola study 06–005 was an open-label, single-dose, mass-balance and metabolic profiling study using 14C-labeled betrixaban in 5 healthy male volunteers. Each subject received a single oral solution containing 40 mg of betrixaban labeled with 100 μCi of 14C. Blood samples were taken serially ov

APA, Harvard, Vancouver, ISO, and other styles

6

Murphy, Grazia, Yasmin Grace, Sadaf Chaudry, and Rita Chamoun. "Betrixaban: A Novel Oral Anticoagulant With a New Niche." Journal of Pharmacy Technology 34, no. 3 (2018): 123–33. http://dx.doi.org/10.1177/8755122518759765.

Full text

Abstract:

Objective: To evaluate the efficacy, safety, and clinical implication of betrixaban for prophylaxis of venous thromboembolism (VTE) in patients with acute medical illness. Data Sources: A search for clinical trials was performed from January 2006 to January 2017 in English language using Clinicaltrials.gov and PubMed/MEDLINE. The following search terms were used: betrixaban, pharmacokinetics, pharmacology, and drug safety. Study Selection: The following limits were used to access the clinical trials: controlled clinical trial, randomized clinical trial, clinical trial, clinical trial phase II,

APA, Harvard, Vancouver, ISO, and other styles

7

Bauer, Kenneth, Bruce Davidson, William Fisher, et al. "A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)." Thrombosis and Haemostasis 101, no. 01 (2009): 68–76. http://dx.doi.org/10.1160/th08-07-0460.

Full text

Abstract:

SummaryBetrixaban is an oral direct inhibitor of factor Xa (FXa) being developed for the prevention of venous thromboembolism (VTE). Its antithrombotic effects had not been previously tested in patients. This exploratory clinical trial in the US and Canada randomized 215 patients undergoing elective total knee replacement (TKR) in a 2:2:1 ratio to receive post-operative betrixaban 15 mg or 40 mg p.o. bid or enoxaparin 30 mg s.c. q12h, respectively, for 10–14 days. The betrixaban dosage was blinded, but enoxaparin was not. Primary efficacy outcome was the incidence of VTE, consisting of deep-ve

APA, Harvard, Vancouver, ISO, and other styles

8

Siriez, Romain, Jonathan Evrard, Jean-Michel Dogné, et al. "Betrixaban: Impact on Routine and Specific Coagulation Assays—A Practical Laboratory Guide." Thrombosis and Haemostasis 118, no. 07 (2018): 1203–14. http://dx.doi.org/10.1055/s-0038-1657772.

Full text

Abstract:

Introduction Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food and Drug Administration for prophylaxis of venous thromboembolism in adult patients hospitalized for an acute illness at risk for thromboembolic complications. Assessment of the anti-coagulant effect of betrixaban may be useful in some situations. Also, clinicians need to know how routine coagulation assays are influenced. Objective The aim of this study is to determine which coagulation assay(s) should be used to assess the impact of betrixaban on haemostasis and provide laboratory guidance for their inter

APA, Harvard, Vancouver, ISO, and other styles

9

Rao Anna, Venkateswara, V. K. Rohini, K. Hemabala, Bhagya Kumar Tatavarti, and Vijaya N. "Evaluation of New Degradation Products Formed Under Stress Conditions of Betrixaban by LCMS/MS: Establishment of HPLC Method for Quantification of Genotoxic Impurities of Betrixaban." International Journal of Advancement in Life Sciences Research 07, no. 04 (2024): 64–78. http://dx.doi.org/10.31632/ijalsr.2024.v07i04.006.

Full text

Abstract:

This study focused to optimize an accurate HPLC method for evaluation of genotoxic impurities of Betrixaban and further structural identification of forced degradation products (DPs) of betrixaban. The analytes were resolved on Zorbax SB C18 (4.6×250mm, 5μm, Agilent) column at 35°C temperature using 75 % aqueous ammonium formate (5 mM) and 50 % ammonium formate in acetonitrile in 60:40 (v/v) in isocratic elution at 1.0 mL/min and 245 nm as detection wavelength. In the optimized experimental conditions, the retention times of the analytes were precisely determined, resulting in retention times

APA, Harvard, Vancouver, ISO, and other styles

10

Gibson, C., Lisa Jennings, Gerald Chi, et al. "Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial." TH Open 02, no. 01 (2018): e16-e24. http://dx.doi.org/10.1055/s-0037-1615288.

Full text

Abstract:

Background Elevated D-dimer concentrations are associated with an increased risk of venous thromboembolism (VTE). However, they may also provide prognostic value. The present analysis sought to study the association of D-dimer levels with VTE event rates and the efficacy of betrixaban versus enoxaparin in the APEX trial. Methods Hospitalized acutely medically ill subjects (n = 7,513) were randomized in a double-dummy double-blind fashion to either extended-duration oral betrixaban (80 mg once daily for 35–42 days) or standard dose subcutaneous enoxaparin (40 mg once daily for 10 ± 4 days) for

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!